晚期结直肠癌抗血管生成药物疗效评价的研究进展

Research progression in response evaluation of antiangiogenic therapy for advanced colorectal cancer

抗血管生成治疗是肾癌、肝癌和结直肠癌等恶性肿瘤治疗手段中的重要组成部分。与细胞毒化疗药物直接杀伤肿瘤细胞不同,抗血管生成药物作用于肿瘤血管,通过抑制肿瘤生长来发挥抗肿瘤作用,如何准确评价其疗效是目前的难题。新的疗效评价标准如肾癌的MASS标准、肝癌的mRECIST标准已被提出,一定程度上弥补了RECIST标准的缺陷。CT形态学标准、磁共振成像、超声造影、PET/CT和循环肿瘤DNA等亦为晚期结直肠癌抗血管生成治疗疗效评价提供了新的方法。本文就晚期结直肠癌的抗血管生成药物疗效评价研究进展作一综述。

Antiangiogenic therapy is an important part of the treatment of malignancy such as kidney cancer,liver cancer and colorectal cancer.Unlike cytotoxic drugs that directly kill cancer cells,antiangiogenic therapy acts on tumor blood vessels and exerts anti-tumor effects by inhibiting tumor growth.Precise response evaluation of antiangiogenic therapy is challenging.New reponse evaluation criteria such as MASS criteria for renal cell carcinoma and mRECIST criteria for hepatocellualar carcinoma have been proposed and make up for the defects of RECIST to some extent.CT morphological criteria,magnetic resonance imaging,contrast enhanced ultrasound,PET/CT and circulating tumor DNA also provide new methods for response evaluation of antiangiogenic therapy for advanced colorectal cancer.This review summarizes the recent advances made in the area of response evaluation of antiangiogenic therapy for advanced colorectal cancer.